Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis

Expert Review of Vaccines

Volumn 11, Issue 5, 2012, Pages 609-628

  Pliaka, Vaia ^a   Kyriakopoulou, Zaharoula ^a   Markoulatos, Panayotis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

immunization schedules; inactivated polio vaccine; mutations; neurovirulence; oral polio vaccine; recombination; vaccine associated paralytic poliomyelitis; vaccine derived polioviruses

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERADICATION THERAPY; GENETIC VARIABILITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; NONHUMAN; PARALYTIC POLIOMYELITIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; VIRUS INACTIVATION; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS RECOMBINATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS VIRULENCE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HUMANS; INFANT; MUTATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK; YOUNG ADULT;

EID: 84862526792     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.28     Document Type: Review

References (236)

1. Racaniello VR. Picornaviridae: the viruses and their replication. In: Fields Virology (5th Edition, Volume I).Knipe DM, Howley PM (Eds.)Lippincott Williams & Wilkins, PA, USA, 765 (2007
2. Brown B, Oberste MS, Maher K, Pallansch MA. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J. Virol. 77(16), 8973-8984 (2003
3. Nathanson N. The pathogenesis of poliomyelitis: what we don't know. Adv. Virus Res. 71, 1-50 (2008
4. Sartwell PE. The incubation period of poliomyelitis. Am. J. Public Health Nations. Health 42(11), 1403-1408 (1952
5. Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Virology (2nd Edition).Fields B, Knipe D (Eds.), Raven Press, NY, USA, 549 (1990
6. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175(Suppl. 1), S176-S182 (1997
7. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhancepotency inactivated and oral polio vaccines. J. Infect. Dis. 163(1), 1-6 (1991
8. Jacques J, Moret H, Minette D et al. Epidemiological, molecular, and clinical features of enterovirus respiratory infections in French children between 1999 and 2005. J. Clin. Microbiol. 46(1), 206-213 (2008
9. Oberste MS, Maher K, Schnurr D et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J. Gen. Virol. 85(Pt 9), 2577-2584 (2004
10. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150(10), 1001-1021 (1999
11. Bodian D. Immunologic classification of poliomyelitis viruses. I. A cooperative program for the typing of one hundred strains. Am. J. Hyg. 54(2), 191-204 (1951
12. Minor PD. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161, 121-154 (1990
13. Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229(4720), 1358-1365 (1985
14. Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu. Rev. Genet. 27, 353-436 (1993
15. Paul AV, Peters J, Mugavero J, Yin J, Van Boom JH, Wimmer E. Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J. Virol. 77(2), 891-904 (2003
16. Domingo E, Escarmis C, Sevilla N et al. Basic concepts in RNA virus evolution. FASEB J. 10(8), 859-864 (1996
17. Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. ASM Press, DC, USA (1995
18. Gmyl AP, Belousov EV, Maslova SV, Khitrina EV, Chetverin AB, Agol VI. Nonreplicative RNA recombination in poliovirus. J. Virol. 73(11), 8958-8965 (1999
19. Kirkegaard K, Baltimore D. The mechanism of RNA recombination in poliovirus. Cell 47(3), 433-443 (1986
20. Pierangeli A, Bucci M, Forzan M, Pagnotti P, Equestre M, Pérez Bercoff R. 'Primer alignment-and-extension': a novel mechanism of viral RNA recombination responsible for the rescue of inactivated poliovirus cDNA clones. J. Gen. Virol. 80(Pt 8), 1889-1897 (1999
21. White KA, Morris TJ. RNA determinants of junction site selection in RNA virus recombinants and defective interfering RNAs. RNA 1(10), 1029-1040 (1995
22. Freistadt MS, Vaccaro JA, Eberle KE. Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol. J. 4, 44 (2007
23. Lai MM. RNA recombination in animal and plant viruses. Microbiol. Rev. 56(1), 61-79 (1992
24. Worobey M, Holmes EC. Evolutionary aspects of recombination in RNA viruses. J. Gen. Virol. 80(Pt 10), 2535-2543 (1999
25. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations. Health 44(5), 563-570 (1954
26. Robertson SE, Traverso HP, Drucker JA et al. Clinical efficacy of a new, enhancedpotency, inactivated poliovirus vaccine. Lancet 1(8591), 897-899 (1988
27. Offit PA. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. Yale University Press, CT, USA (2005
28. Melnick JL, Brennan JC. Monkey neurovirulence of attenuated poliovirus vaccines being used in field trials. In: Live Polio Virus Vaccines. PAHO, DC, USA, 65-101 (1959
29. Chumakov MP. The effect of mass peroral immunisation by live vaccines from Sabin strains on the epidemiological process of poliomyelitis. J. Hyg. Epidemiol. Microbiol. Immunol. 4, 287-288 (1960
30. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J. Am. Med. Assoc. 164(11), 1216-1223 (1957
31. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151(3), 420-436 (1985
32. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1, 115-118 (1973
33. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type1 poliovirus Sabin vaccine. J. Virol. 69(8), 4972-4978 (1995
34. Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F. Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J. Virol. 69(9), 5278-5286 (1995
35. Macadam AJ, Arnold C, Howlett J et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type3 strain of poliovirus in vaccinees. Virology 172(2), 408-414 (1989
36. Macadam AJ, Pollard SR, Ferguson G et al. The 5' noncoding region of the type2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181(2), 451-458 (1991
37. Bodian D. Discussion. Infection and immunity in poliomyelitis. In: Papers and Discussions Presented at The Third International Poliomyelitis Conference. JB Lippincott, PA, USA, 196-201 (1954
38. Plotkin SA, Koprowski H, Stokes J Jr. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 23(6), 1041-1062 (1959
39. Sutter R, Cochi S, Melnick JL. Live attenuated poliovirus vaccine. In: Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds.),WB Saunders, PA, USA, 364-408 (1999
40. Fine PE. Polio: measuring the protection that matters most. J. Infect. Dis. 200(5), 673-675 (2009
41. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine using countries. Wkly. Epidemiol. Rec. 78(28), 241-250 (2003
42. Fox JP. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev. Infect. Dis. 6(Suppl. 2), S352-S355 (1984
43. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev. Infect. Dis. 6(Suppl. 2), S361-S368 (1984
44. Sabin AB. Recent studies and field tests with a live attenuated poliovirus vaccine. In: First International Conference on Live Poliovirus Vaccines, Papers Presented and Discussions Held. Pan American Sanitary Bureau, DC, USA, 44, 14-33 (1959
45. Horstmann DM, Niederman JC, Paul JR. Attenuated type1 poliovirus vaccine; its capacity to infect and to spread from vaccinees within an institutional population. J. Am. Med. Assoc. 170(1), 1-8 (1959
46. Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J. Infect. Dis. 182(1), 1-5 (2000
47. Svennerholm AM, Hanson LA, Holmgren J et al. Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J. Infect. Dis. 143(5), 707-711 (1981
48. Zaman S, Carlsson B, Jalil F et al. Comparison of serum and salivary antibodies in children vaccinated with oral live or parenteral inactivated poliovirus vaccines of different antigen concentrations. Acta Paediatr. Scand. 80(12), 1166-1173 (1991
49. Carlsson B, Zaman S, Mellander L, Jalil F, Hanson LA. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination. J. Infect. Dis. 152(6), 1238-1244 (1985
50. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162(6), 1291-1297 (1990
51. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bull. World Health Organ. 74(3), 253-268 (1996
52. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med. 356(15), 1536-1544 (2007
53. Laassri M, Lottenbach K, Belshe R et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J. Infect. Dis. 192(12), 2092-2098 (2005
54. Dick GW, Dane DS, McAlister J, Briggs M, Nelson R, Field CM. Vaccination against poliomyelitis with live virus vaccines. 7. Effect of previous Salk vaccination on virus excretion. Br. Med. J. 2(5247), 266-269 (1961
55. Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type1 poliomyelitis epidemic. Am. J. Hyg. 76, 173-195 (1962
56. Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch M. Control of paralytic poliomyelitis in the United States. Rev. Infect. Dis. 6(Suppl. 2), S424-S426 (1984
57. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev. Infect. Dis. 6(Suppl. 2), S457-S460 (1984
58. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bull. World Health Organ. 60(2), 231-242 (1982
59. Salk D, Van Wezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 2(8415), 1317-1321 (1984
60. Rümke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect. 115(2), 289-298 (1995
61. Böttiger M, Fagraeus A. Polio vaccination in Sweden. Rev. Infect. Dis. 2, 274-276 (1980
62. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev. Infect. Dis. 6(Suppl. 2), S457-S460 (1984
63. Plotkin SA, Vidor E. Poliovirus vaccine- inactivated. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds.),WB Saunders Company, PA, USA, 625-649 (2004
64. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14(8), 735-746 (1996
65. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26(39), 4978-4983 (2008
66. Van Wezel AL, Van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 41, 159-168 (1978
67. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 16(3), 312-322 (1997
68. Rennels MB. Need for polio boosters after age two years. Vaccine 27(2), 179-180 (2009
69. Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343(8909), 1331-1337 (1994
70. Sabin AB, Michaels RH, Spigland I, Pelon W, Rhim JS, Wehr RE. Community-wide use of oral poliovirus vaccine. Efectiveness of the Cincinnati program. Am. J. Dis. Child. 101, 546-567 (1961
71. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J. Infect. Dis. 171(5), 1097-1106 (1995
72. de Quadros CA, Andrus JK, Olivé JM, Carrasco P. Strategies for poliomyelitis eradication in developing countries. Public Health Rev. 21(1-2), 65-81 (1993-1994
73. Kim-Farley RJ, Rutherford G, Lichfield P et al. Outbreak of paralytic poliomyelitis, Taiwan. Lancet 2(8415), 1322-1324 (1984
74. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds.).Saunders Elsevier, PA, USA, 631-685 (2008
75. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccinederived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59, 587-635 (2005
76. CDC. Progress toward interruption of wild poliovirus transmission- worldwide, 2008. Morb. Mort. Wkly. Rep. 58(12), 308-312 (2009
77. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27(20), 2649-2652 (2009
78. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am. J. Epidemiol. 162(4), 358-372 (2005
79. Thompson KM, Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am. J. Public Health 98(7), 1322-1330 (2008
80. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297(5583), 1016-1018 (2002
81. Peart AF, Rhodes AJ. An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can. J. Public Health. 40(10), 405-419 (1949
82. Rhodes AJ, Chapman M. Some observations on interference between neurotropic viruses. Can. J. Res. 27(6 Sect. E), 341-348 (1949
83. CDC. Progress toward global eradication of poliomyelitis, 2001. Morb. Mortal. Wkly Rep. 51(12), 253-256 (2002
84. Polio Global Eradication Initiative: annual report 2012. WHO, Geneva, Switzerland (2011
85. CDC. Progress toward global eradication of poliomyelitis, 1999. Morb. Mortal. Wkly Rep. 49, 349-354 (2002
86. Wassilak S, Oblapenko G, Dittmann S. Progress in Europe towards the goal of poliomyelitis eradication. Euro Surveill. 2(5), 39-41 (1997
87. Arita I, Nakane M. Road map for polio eradication-establishing the link with Millennium Development Goal no. 4 for child survival. Jpn. J. Infect. Dis. 61(3), 169-174 (2008
88. Grassly NC, Fraser C, Wenger J et al. New strategies for the elimination of polio from India. Science 314(5802), 1150-1153 (2006
89. Grassly NC, Wenger J, Durrani S et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369(9570), 1356-1362 (2007
90. el-Sayed N, el-Gamal Y, Abbassy AA et al. Monovalent type1 oral poliovirus vaccine in newborns. N. Engl. J. Med. 359(16), 1655-1665 (2008
91. Graf H. Manufacturing and supply of monovalent oral polio vaccines. Biologicals 34(2), 141-144 (2006
92. WHO. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol. Rec. 84(29), 289-290 (2009
93. Oostvogel PM, Van Wijngaarden JK, Van der Avoort HG et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93. Lancet 344(8923), 665-670 (1994
94. Ciofi Degli Atti M, Prevots R, Sallabanda A et al. Polio outbreak in Albania, 1996. Euro Surveill. 2(5), 37-39 (1997
95. Kyriakopoulou Z, Kottaridi C, Dedepsidis E, Bolanaki E, Levidiotou-Stefanou S, Markoulatos P. Molecular characterization of wild-type polioviruses isolated in Greece during the 1996 outbreak in Albania. J. Clin. Microbiol. 44(3), 1150-1152 (2006
96. CDC. Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005. Morb. Mort. Wkly Rep. 55(6), 145-150 (2006
97. CDC. Wild poliovirus type 1 and type 3 importations-15 countries, Africa, 2008-2009. Morb. Mort. Wkly Rep. 58(14), 357-362 (2009
98. Yakovenko ML, Cherkasova EA, Rezapkin GV et al. Antigenic evolution of vaccinederived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80(6), 2641-2653 (2006
99. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-derived polioviruses in the environment. J. Gen. Virol. 83(Pt 5), 1107-1111 (2002
100. Adu F, Iber J, Bukbuk D et al. Isolation of recombinant type2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res. 127(1), 17-25 (2007
101. Crainic R, Couillin P, Blondel B, Cabau N, Boué A, Horodniceanu F. Natural variation of poliovirus neutralization epitopes. Infect. Immun. 41(3), 1217-1225 (1983
102. Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67(Pt 4), 693-706 (1986
103. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J. Virol. 74(16), 7381-7390 (2000
104. Yang CF, Chen HY, Jorba J et al. Intratypic recombination among lineages of type1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79(20), 12623-12634 (2005
105. Odoom JK, Yunus Z, Dunn G, Minor PD, Martin J. Changes in population dynamics during long-term evolution of Sabin type1 poliovirus in an immunodeficient patient. J. Virol. 82(18), 9179-9190 (2008
106. Cuervo NS, Guillot S, Romanenkova N et al. Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees. J. Virol. 75(13), 5740-5751 (2001
107. Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M. Comparison of poliovirus recombinants: accumulation of point mutations provides further adVantages. J. Gen. Virol. 90(Pt 8), 1859-1868 (2009
108. Blomqvist S, Bruu AL, Stenvik M, Hovi T. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J. Gen. Virol. 84(Pt 3), 573-580 (2003
109. Martin J, Samoilovich E, Dunn G et al. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J. Virol. 76(21), 10921-10928 (2002
110. Georgescu MM, Delpeyroux F, Tardy-Panit M et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 68(12), 8089-8101 (1994
111. Christodoulou C, Colbere-Garapin F, Macadam A et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64(10), 4922-4929 (1990
112. Georgescu MM, Balanant J, Macadam A et al. Evolution of the Sabin type1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 71(10), 7758-7768 (1997
113. Martin J, Odoom K, Tuite G et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78(24), 13839-13847 (2004
114. Gutiérrez AL, Denova-Ocampo M, Racaniello VR, del Angel RM. Attenuating mutations in the poliovirus 5' untranslated region alter its interaction with polypyrimidine tract-binding protein. J. Virol. 71(5), 3826-3833 (1997
115. Cello J, Toyoda H, Dejesus N, Dobrikova EY, Gromeier M, Wimmer E. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J. Med. Virol. 80(2), 352-359 (2008
116. Malnou CE, Werner A, Borman AM, Westhof E, Kean KM. Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild-type poliovirus type1 context. J. Biol. Chem. 279(11), 10261-10269 (2004
117. De Jesus N, Franco D, Paul A, Wimmer E, Cello J. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J. Virol. 79(22), 14235-14243 (2005
118. Pliaka V, Filliponi ME, Kyriakopoulou Z et al. Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece. Clin. Microbiol. Infect. 17(10), 1554-1562 (2011
119. Pliaka V, Dedepsidis E, Kyriakopoulou Z et al. Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. Virus Genes 40(2), 200-211 (2010
120. Pliaka V, Kyriakopoulou Z, Tsakogiannis D et al. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains. Eur. J. Clin. Microbiol. Infect. Dis. 29(12), 1513-1523 (2010
121. Horie H, Yoshida H, Matsuura K et al. Isolation of vaccine-derived type1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J. Med. Virol. 68(3), 445-451 (2002
122. Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadopoulou I, Levidiotou S, Markoulatos P. Use of mutational pattern in 5'-NCR and VP1 regions of polioviruses for molecular diagnosis. Mol. Cell. Probes 21(4), 267-275 (2007
123. John TJ. Vaccine-associated paralytic polio in India. Bull. World Health Organ. 80(11), 917 (2002
124. Strebel PM, Sutter RW, Cochi SL et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virusassociated disease. Clin. Infect. Dis. 14(2), 568-579 (1992
125. Buttinelli G, Donati V, Fiore S et al. Nucleotide variation in Sabin type2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 84(Pt 5), 1215-1221 (2003
126. Cherkasova EA, Yakovenko ML, Rezapkin GV et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J. Virol. 79(2), 1062-1070 (2005
127. Manor Y, Handsher R, Halmut T et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J. Clin. Microbiol. 37(6), 1670-1675 (1999
128. Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull. World Health Organ. 80(3), 210-216 (2002
129. Otelea D, Guillot S, Furione M et al. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev. Biol. Stand. 78, 33-38 (1993
130. Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type3. J. Virol. 78(20), 11097-11107 (2004
131. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63(2), 353-362 (1990
132. Minor PD, Dunn G. The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. J. Gen. Virol. 69 (Pt 5), 1091-1096 (1988
133. Macadam AJ, Pollard SR, Ferguson G et al. Genetic basis of attenuation of the Sabin type2 vaccine strain of poliovirus in primates. Virology 192(1), 18-26 (1993
134. Minor PD. The molecular biology of poliovaccines. J. Gen. Virol. 73 (Pt 12), 3065-3077 (1992
135. Friedrich F. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol. 40(3), 157-170 (1996
136. Friedrich F, Da-Silva EF, Schatzmayr HG. type2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil. Acta Virol. 40(1), 27-33 (1996
137. King AM. Preferred sites of recombination in poliovirus RNA: an analysis of 40 intertypic cross-over sequences. Nucleic Acids Res. 16(24), 11705-11723 (1988
138. Cherkasova EA, Korotkova EA, Yakovenko ML et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76(13), 6791-6799 (2002
139. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196(1), 199-208 (1993
140. Lipskaya GY, Muzychenko AR, Kutitova OK et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J. Med. Virol. 35(4), 290-296 (1991
141. Blomqvist S, Savolainen C, Laine P et al. Characterization of a highly evolved vaccine-derived poliovirus type3 isolated from sewage in Estonia. J. Virol. 78(9), 4876-4883 (2004
142. Mueller JE, Bessaud M, Huang QS et al. Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina. Appl. Environ. Microbiol. 75(5), 1395-1401 (2009
143. Zurbriggen S, Tobler K, Abril C et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl. Environ. Microbiol. 74(18), 5608-5614 (2008
144. Combiescu M, Guillot S, Persu A et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch. Virol. 152(4), 727-738 (2007
145. Driesel G, Diedrich S, Kunkel U, Schreier E. Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Eur. J. Epidemiol. 11(6), 647-654 (1995
146. Kew O, Morris-Glasgow V, Landaverde M et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type1 vaccine-derived poliovirus. Science 296(5566), 356-359 (2002
147. Karakasiliotis I, Markoulatos P, Katsorchis T. Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol. Cell. Probes 18(2), 103-109 (2004
148. Dedepsidis E, Pliaka V, Kyriakopoulou Z et al. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant. FEMS Immunol. Med. Microbiol. 52(3), 343-351 (2008
149. Blomqvist S, Savolainen-Kopra C, Paananen A et al. Recurrent isolation of poliovirus 3 strains with chimeric capsid protein Vp1 suggests a recombination hot-spot site in Vp1. Virus Res. 151(2), 246-251 (2010
150. Karakasiliotis I, Paximadi E, Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus. J. Gen. Virol. 86(Pt 11), 3137-3142 (2005
151. Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P. Genomic analysis of recombinant sabin clinical isolates. Virus Genes 32(2), 203-210 (2006
152. Boot HJ, Schepp RM, Van Nunen FJ, Kimman TG. Rapid RT-PCR amplification of full-length poliovirus genomes allows rapid discrimination between wild-type and recombinant vaccine-derived polioviruses. J. Virol. Methods 116(1), 35-43 (2004
153. Liu HM, Zheng DP, Zhang LB, Oberste MS, Kew OM, Pallansch MA. Serial recombination during circulation of type1 wild-vaccine recombinant polioviruses in China. J. Virol. 77(20), 10994-11005 (2003
154. Dedepsidis E, Kyriakopoulou Z, Pliaka V, Markoulatos P. Correlation between recombination junctions and RNA secondary structure elements in poliovirus Sabin strains. Virus Genes 41(2), 181-191 (2010
155. Kilpatrick DR, Ching K, Iber J et al. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J. Clin. Microbiol. 42(9), 4313-4315 (2004
156. Pliaka V, Dedepsidis E, Kyriakopoulou Z et al. A new RT-PCR assay for the identification of the predominant recombination types in 2C and 3D genomic regions of vaccine-derived poliovirus strains. Mol. Cell. Probes 24(3), 115-123 (2010
157. WHO. Expanding contributions of the Global Laboratory Network for Poliomyelitis Eradication, 2000-2001. Wkly Epidemiol. Rec. 77, 133 (2002
158. Manual for the virological investigation of polio (WHO/EPI/GEN/97.01). WHO, Geneva, Switzerland (2004
159. Agol VI. Vaccine-derived polioviruses. Biologicals 34(2), 103-108 (2006
160. WHO. Global update on vaccine-derived polioviruses, January 2006-August 2007. Wkly Epidemiol. Rec. 82, 337-344 (2007
161. WHO. Vaccine-derived polioviruses detected worldwide, July 2009-March 2011. Wkly Epidemiol. Rec. 86, 277-288 (2011
162. Update on vaccine-derived polioviruses - worldwide, January 2008-June 2009. MMWR Morb. Mortal. Wkly Rep. 58, 1002-1006 (2009
163. Kew OM, Wright PF, Agol VI et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 82(1), 16-23 (2004
164. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE 3(10), e3433 (2008
165. Laboratory surveillance for wild and vaccine-derived polioviruses - worldwide, January 2007 June 2008. MMWR Morb. Mortal. Wkly Rep. 57, 967-970 (2008
166. Shimizu H, Thorley B, Paladin FJ et al. Circulation of type1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 78(24), 13512-13521 (2004
167. Liang X, Zhang Y, Xu W et al. An outbreak of poliomyelitis caused by type1 vaccinederived poliovirus in China. J. Infect. Dis. 194(5), 545-551 (2006
168. Estivariz CF, Watkins MA, Handoko D et al. A large vaccine-derived poliovirus outbreak on Madura Island - Indonesia, 2005. J. Infect. Dis. 197(3), 347-354 (2008
169. Update on vaccine-derived polioviruses. MMWR Morb. Mortal. Wkly Rep. 55, 1093-1097 (2006
170. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerging Infect. Dis. 9(7), 885-887 (2003
171. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am. J. Epidemiol. 110(6), 672-692 (1979
172. Yang CF, Naguib T, Yang SJ et al. Circulation of endemic type2 vaccinederived poliovirus in Egypt from 1983 to 1993. J. Virol. 77(15), 8366-8377 (2003
173. Thorley B, Paladin F, Shimizu H. Presented at: XIIth International Congress of Virology. Paris, France, 27 July-1 August 2002.
174. Riquet FB, Blanchard C, Jegouic S et al. Impact of exogenous sequences on the characteristics of an epidemic type2 recombinant vaccine-derived poliovirus. J. Virol. 82(17), 8927-8932 (2008
175. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 34(2), 117-122 (2006
176. Halsey NA, Pinto J, Espinosa-Rosales F et al.; Polio Project Team. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. World Health Organ. 82(1), 3-8 (2004
177. Khetsuriani N, Prevots DR, Quick L et al. Persistence of vaccine-derived poliovir uses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188(12), 1845-1852 (2003
178. MacLennan C, Dunn G, Huissoon AP et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363(9420), 1509-1513 (2004
179. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. (Basel) 105, 75-80 (2001
180. Avellón A, Cabrerizo M, de Miguel T et al. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerging Infect. Dis. 14(11), 1807-1809 (2008
181. Martin J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74(7), 3001-3010 (2000
182. Sutter R, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 11, 426-438 (1994
183. Kew OM, Sutter RW, Nottay BK et al. Prolonged replication of a type1 vaccinederived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36(10), 2893-2899 (1998
184. Cernáková B, Sobotová Z, Rovny I, Bláhova S, Roivainen M, Hovi T. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur. J. Clin. Microbiol. Infect. Dis. 24(6), 438-439 (2005
185. Shulman LM, Manor Y, Handsher R et al. Molecular and antigenic characterization of a highly evolved derivative of the type2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38(10), 3729-3734 (2000
186. Dedepsidis E, Kyriakopoulou Z, Pliaka V et al. Retrospective characterization of a vaccine-derived poliovirus type1 isolate from sewage in Greece. Appl. Environ. Microbiol. 73(21), 6697-6704 (2007
187. Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature 434(7034), 699-700 (2005
188. Aylward RB, Sutter RW, Heymann DL. Policy. OPV cessation-the final step to a 'polio-free' world. Science 310(5748), 625-626 (2005
189. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat. Rev. Microbiol. 5(12), 952-958 (2007
190. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev. Med. Virol. 13(5), 277-291 (2003
191. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol. Rec. 81(15), 137-144 (2006
192. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28(6), 573-579 (2010
193. Wyman O. Global post-eradication IPV supply and demand assessment: integrated findings. Bill and Melinda Gates Foundation, WA, USA (2009
194. Dayan GH, Thorley M, Yamamura Y et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J. Infect. Dis. 195(1), 12-20 (2007
195. Griffiths UK, Botham L, Schoub BD. The cost-effectiveness of alternative polio immunization policies in South Africa. Vaccine 24(29-30), 5670-5678 (2006
196. Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 12(6), E7-E8 (2007
197. Pliaka V, Ruether IG, Kyriakopoulou Z et al. A seroprevalence study of poliovirus antibody against a collection of recombinant and non-recombinant poliovirus vaccine strains in the population of southern Greece. Clin. Microbiol. Infect. 16(11), 1672-1675 (2010
198. Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect. 11(1), 68-71 (2005
199. Mastroeni I, Patti AM, Fabrizi A et al. Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 15(6-7), 747-750 (1997
200. White PM, Green J. Prevalence of antibody to poliovirus in England and Wales 1984-6. Br. Med. J. (Clin. Res. Ed.) 293(6555), 1153-1155 (1986
201. Frantzidou-Adamopoulou F. Poliomyelitis cases in northern Greece during 1976-1990. Eur. J. Epidemiol. 8(1), 112-113 (1992
202. Yakovenko ML, Korotkova EA, IVanova OE et al. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J. Virol. 83(7), 3402-3406 (2009
203. Rakoto-Andrianarivelo M, Guillot S, Iber J et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog. 3(12), e191 (2007
204. Romanenkova NI, Guillot S, Rozaeva NR, Crainic R, Bichurina MA, Delpeyroux F. Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples. J. Clin. Microbiol. 44(11), 4077-4084 (2006
205. WHO. Informal consultation of the Global Polio Laboratory Network. Wkly Epidemiol. Rec. 83, 261-268 (2008
206. Cherkasova E, Laassri M, Chizhikov V et al. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl Acad. Sci. USA. 100(16), 9398-9403 (2003
207. Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from liveattenuated Sabin strains. Vaccine 25(41), 7041-7046 (2007
208. WHO. Improving IPV. The Polio Pipeline 1, 2-3 (2008
209. WHO. Update on improving IPV. The Polio Pipeline 3, 3 (2009
210. WHO. Polio Research Committee outcomes. The Polio Pipeline 3, 1 (2009
211. Kreeftenberg H, Van der Velden T, Kersten G, Van der Heuvel N, de Bruijn M. Technology transfer of Sabin IPV to new developing country markets. Biologicals 34(2), 155-158 (2006
212. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl Acad. Sci. USA 93(6), 2370-2375 (1996
213. Macadam AJ, Ferguson G, Stone DM et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80(17), 8653-8663 (2006
214. Agol VI, Pilipenko EV, Slobodskaya OR. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. J. Biotechnol. 44(1-3), 119-128 (1996
215. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154-161 (2008
216. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280(27), 25706-25716 (2005
217. Burns CC, Shaw J, Campagnoli R et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80(7), 3259-3272 (2006
218. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80(19), 9687-9696 (2006
219. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4(3), 239-248 (2008
220. Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis. 47(12), 1587-1592 (2008
221. WHO. The poliovirus antivirals initiative. The Polio Pipeline 3, 4 (2009
222. De Palma AM, Pürstinger G, Wimmer E et al. Potential use of antiviral agents in polio eradication. Emerging Infect. Dis. 14(4), 545-551 (2008
223. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication NRC. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. National Academies Press, DC, USA (2006
224. Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 79(3), 179-187 (2008
225. Bablanian R, Eggers HJ, Tamm I. Inhibition of enterovirus cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole. J. Bacteriol. 91(3), 1289-1294 (1966
226. Shimizu H, Agoh M, Agoh Y et al. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74(9), 4146-4154 (2000
227. Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69(7), 4189-4197 (1995
228. Thys B, De Palma AM, Neyts J, Andries K, Vrijsen R, Rombaut B. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Antiviral Res. 78(3), 278-281 (2008
229. Watson KG, Brown RN, Cameron R et al. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 46(15), 3181-3184 (2003
230. Buontempo PJ, Cox S, Wright-Minogue J et al. SCH 48973: a potent, broadspectrum, antienterovirus compound. Antimicrob. Agents Chemother. 41(6), 1220-1225 (1997
231. McKinlay MA, Steinberg BA. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob. Agents Chemother. 29(1), 30-32 (1986
232. Binford SL, Maldonado F, Brothers MA et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 49(2), 619-626 (2005
233. Patick AK, Brothers MA, Maldonado F et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 49(6), 2267-2275 (2005
234. Geller R, Vignuzzi M, Andino R, Frydman J. Evolutionary constraints on chaperonemediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21(2), 195-205 (2007
235. Maynell LA, Kirkegaard K, Klymkowsky MW. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66(4), 1985-1994 (1992
236. De Jesus NH. Epidemics to eradication: the modern history of poliomyelitis. Virol. J. 4, 70 (2007)